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ABSTRACT
Glutathione S-transferases (GSTs) are enzymes involved in the detox­
ification of xenobiolics and are divided into four subclasses, a, p, tt, and 
0, with different although overlapping substrate specificities. Most human 
gastrointestinal tumors contain increased amounts of GST-tt and GST 
enzyme activity. The relationship between GST parameters and tumor 
and patient characteristics, including overall survival, were studied ret­
rospectively in 100 primary colorectal adenocarcinomas. Levels of GST-a, 
GST-ji, GST-tt, and GST enzyme activity were not related to the Dukes 
stage, differentiation grade, localization, histological type and diameter of 
the tumor, or gender and age of the patient. Fifty-seven patients died 
(median survival, 21 months; range, 1-65 months) during follow-up, and 
43 patients were still alive at the closing date of the study (median 
follow-up, 68 months; range, 60-87 months). Optimal dichotomization 
and uni- and multivariate analyses were done with the Cox proportional 
hazard model. Multivariate analysis with all clinicopathological parame­
ters revealed higher Dukes stage (hazard ratio, 2.7; P < 0.001) and older 
age (hazard ratio, 2.8; P =  0.001) to be the only independent prognostic 
variables for overall survival. In contrast to GST-a and GST-^i, high levels 
of GST-tt (hazard ratio, 3.1; P — 0.002) and GST enzyme activity (hazard 
ratio, 2.0; P = 0.020) in the tumors were found to have a significant 
prognostic value independent from the clinicopathological parameters 
when added separately to this Cox model. Thus, this study indicates that 
GST subclass levels in colorectal adenocarcinomas are not related to 
clinicopathological parameters and that the GST-7T level and GST enzyme 
activity have a prognostic value for the overall survival of the patients.
INTRODUCTION
GSTs3 are enzymes that catalyze the nuclcophilic addition of glu­
tathione to electrophilic centers of a wide variety of compounds. This 
reaction is the first step in the formation of mercapturic acids, a 
pathway resulting mostly in the elimination of potentially toxic com­
pounds (1, 2). GSTs are also involved in the metabolism of several 
types of anticancer drugs (3) and are overexpressed in many human 
refractory tumors (4). On the basis of structural, physicochemical, 
enzymatic, and immunological properties, cytosolic GSTs are divided 
into three classes: a, f±, and tt (2). Recently, a fourth class of GST (0) 
has been described (5).
GST-tt is the predominant subclass detected in colonic tissue in 
both normal mucosa and adenocarcinomas, whereas GST-ju, and 
GST-a are present at much lower concentrations (6). Primary colo­
rectal tumors contain higher amounts of GST-7r and GST enzyme 
activity compared to normal mucosa, whereas the minor amounts of 
GST-a and GST-jw appear to be down-regulated within the tumor 
(6-9). Not only colorectal carcinomas but also tumors from stomach, 
urinary bladder, uterine cervix, and lung contain increased amounts of 
GST-tt when compared to the adjacent normal tissue (4), suggesting
Received 1/11/95; accepted 4/19/95.
The costs of publication of this article were defrayed in part by the payment of page 
charges. This article must therefore be hereby marked advertisement in accordance with 
18 U.S.C. Section 1734 solely to indicate this fact.
1 This study was supported by Dutch Cancer Society Grants NUKC 92-33 (T. P. J. M.), 
I KW 89-9 (C. F. M. S.), and NKB-KWF oaa 92-18 (S. G.).
2 To whom requests for reprints should be addressed.
3 The abbreviations used arc: GST, glutathione .S'-transferase; HR, hazard ratio.
that high levels of this GST subclass may offer some advantage to 
cancer cells. In a recent study, Gilbert et al. (10) described that high 
levels of GST-ir in the tumor may be an important predictor of early 
recurrence and death in node-negative breast cancer patients. In the 
present study we examined the relationship of GST enzyme activity 
and the levels of GST classes a, fi} and tt in primary colorectal 
adenocarcinomas with tumor and patient characteristics, including 
overall survival.
PATIENTS AND METHODS
Characteristics of Patients and Tumors. Specimens of histologically 
confirmed colorectal adenocarcinomas were obtained from 100 patients (58 
men; median age, 68 years; range, 46-90 years; and 42 women, median age, 
67 years; range, 44-89 years) who were operated on at the University Hospital 
Leiden during the period December 1983 through February 1988. A represent­
ative part of the tumor was selected by the pathologist and stored at -70°C. 
Tumors were classified according to Dukes (11) as modified by Astler and 
Coller (12) and Beart et al, (13) as follows: Dukes stage A, n - 4; B, n = 50; 
C, n = 34; or D, n — 12. Thirty-five carcinomas were located in the right side 
(from caecum to splenic flexure) and 65 were loeated in the left side (from 
splenic flexure to end of rectum) of the colorectum. Diameter, differentiation 
grade (54 poorly and 46 moderately/well differentiated), and histological type 
of the tumor (25 mucin producing and 75 non-mucin producing) were registered.
All patients received primary surgical therapy. They entered the study at the 
operation date and had a clinical follow-up for local recurrence and/or metas­
tasis and survival for at least 5 years. Patient time experience ended in the 
event of death or at the closing date of the study, May 1993. O f the 100 patients 
included in the study, 57 died during the follow-up (median survival, 21 
months; range, 1-65 months), and 31 patients (54%) had evidence of recur­
rence during that period. Forty-three patients were alive at the closing date of 
the study (median follow-up, 68 months; range, 60-87 months), and four (9%) 
of these had evidence of recurrent disease. Of the 35 patients with recurrent 
disease, 6 were operated on, another 6 received radiotherapy, and 4 were 
treated with anticancer drugs, whereas 19 patients received no additional 
anticancer treatment.
The study was approved by the local medical ethical review committee. 
Quantification of GST Enzyme Activity and GST Subclasses. Cytosolic 
fractions were prepared as described before (6). Protein concentrations were 
determined according to Lowry et a l (14). GST enzyme activity was assayed 
by the method of Habig et al, (15) with the use of l-chloro-2,4-dinitrobenzene 
as a substrate. Tumor cytosols were subjected to SDS-PAGE and subsequent 
Western blotting (6). Western blots were incubated with mAbs against GST-a, 
GST-ju,, and GST-ir, and the specific binding of the mAbs to their antigens was 
detected as described previously (6). Staining intensity was quantified by laser 
densitometry (Ultroscan XL, LKB, Bromma, Sweden) with the use of purified 
GSTs as marker proteins. The detection limit of this method is approximately 
40 ng/mg protein, and within- and between-assay variation is 10-15%.
Statistical Analyses. Univariate and multivariate survival analyses were 
performed with the Cox’s proportional hazard model (16) with the use of the 
EGRET statistical package (SERC Corp., Seattle, WA). All clinicopathologi­
cal parameters studied were dichotomized. The cutoff points of age, diameter, 
and GST parameters were determined by increasing the value until the level of 
best discrimination was found with the use of Cox’s univariate survival 
analysis, i.e., optimal dichotomization. Multivariate survival analyses were 
performed by separately adding the GST variables to a model containing all 
clinicopathological parameters (localization, diameter, differentiation grade, 
histological type, and Dukes stage of the tumor, together with gender and age
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of the patient) in order to estimate their independent prognostic value in the 
overall survival. Overall survival curves were constructed by the method of 
Kaplan and Meier (17). Two by two tables obtained after dichotomization 
of both clinicopathological and GST parameters were tested with the use of the
test. Significance of the differences in GST activity and GST subclass levels 
between tumors, dichotomized according to clinicopathological parameters, 
were determined with the use of the Mann-Whitney U test. Besides dichoto- 
mization, parameters were also categorized into three or four subgroups, and 
significance of differences was evaluated with the use of the Kruskall-Wallis 
analysis. Associations between GST parameters were studied with the Spear­
man rank correlation procedure. All data are given as mean ± SEM. Statistical 
values of P < 0.05 were considered significant.
RESULTS
GST-a was detected in 22 of the 100 tumors examined, and 40 tumors 
were positive for GST-/x. GST-71 was detected in all specimens investi­
gated and was the major GST subclass in 97 tumor samples; only 3 
tumors contained slightly more GST-jx. The distribution of the concen­
trations of GST subclasses and GST enzyme activity is shown in Fig. 1 . 
Mean levels of GST-a, GST-jlxs and GST-7T were 0.09 ± 0.03, 
0.25 ± 0.05, and 3.57 ± 0.20 fxg/mg protein, respectively. Mean GST 
enzyme activity was 261 ± 13 nmol/min/mg protein.
When tumors were divided into two or more subgroups according 
to the clinicopathological parameters, no significant differences in
GST subclass levels or GST enzyme activity were noticed (Table 1). 
There was no association between GST-/X and GST-a, and these two 
GST subclasses were not correlated with GST-7T or GST enzyme 
activity. However, GST enzyme activity was correlated significantly 
(r = 0.54; P < 0.001) with GST-7T level in the tumors.
Tumors from patients who survived had higher GST-pc and lower 
GST-a and GST-tt levels, as well as lower GST enzyme activities, 
than tumors from patients who had died, but differences did not reach 
significance (Table 2). Univariate analysis of dichotomized patient 
and tumor characteristics showed that only the age of the patient 
(< versus >66.1 years; HR, 3.1.4; P < 0.001) and Dukes stage of the 
tumor (A + B versus C + D; HR, 2.71; P < 0,001) were associated 
significantly with overall survival (see Fig. 2, A and B, and Table 3). 
After determining the best discrimination point as cutoff level be­
tween survivors and nonsurvivors, a high GST-a (>0.14 jug/mg pro­
tein; HR, 2.40; P = 0.008; Fig. 2C) or a low GST-jx (<0.18 /xg/mg 
protein; HR, 1.95; P = 0.040; Fig. 2D) level in the carcinoma 
appeared to be associated with significantly shorter overall survival. A 
high GST-7t value (>5.30 jxg/mg protein; HR, 1.92; P = 0.054) and 
a high GST enzyme activity (>243 nmol/min/mg protein; HR, 1.66; 
P =  0.058) also tended to be associated with poor prognosis, but only 
borderline significances were obtained in the univariate analyses 
(Table 4). The relationship between dichotomized clinicopathological
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Fig. 1. Distribution of glutathione 5-transferase class a (A), /x (B), and tt (C) and glutathione 5-transferase enzyme activity (D) in human primary colorectal carcinomas.
2697
GLUTATHIONE 5-TRANSFERASES IN COLORECTAL CANCER
Table 1 Glutathione S-transferase subclass composition and glutathione S-transfcrase enzyme activity in colorectal tumors dichotomized according to various
clinicopathological parametersa
Parameter
dichotomized
(")
GST-a 
(jug/mg protein)
GST-/X 
(jug/mg protein)
GST-tt
(/xg/mg protein)
GST enzyme 
activity 
(nmol/min/mg protein)
Gender
Male (58) 0.11 ±0.04* 0.18 ±0.06
3.48 ± 0.26 256 ± 16
Female (42) 0.05 i  0.03 0.33 ± 0.07 3.69 + 0.33
268 ± 23
Age 
<66.1 yrs (43) 0.06 + 0,04 0.29 ± 0.07 3.38 ± 0.28
266 ± 21
>66.1 yrs (57) 0.10 + 0.04 0.21 ± 0.06 3.71 + 0.29 256 ± 17
Localization
Left (65) 0.08 ± 0.04 0.22 ± 0.06 3.53 + 0.24 258 ± 16
Right (35) 0.10 ±0.04 0.29 ± 0.08 3.65 ± 0.38 266 ± 23
Differentiation grade
Poor (54) 0.05 ± 0.02 0.25 ± 0.06 3.80 ± 0.30 250 ± 18
\ /
Moderate/well (46) 0.13 ±0.05 0.25 ± 0.07 3.30 ± 0.27 274 + 20
Histological type
Nonmucinous (75) 0.06 ± 0.02 0.25 ± 0.05 3.51 ± 0.23 271 ± 16
Mucinous (25) 0.16 ± 0.09 0.24 ± 0.09 3.77 t  0.43 231 ± 24
Dukes stage
A + B (54) 0.08 ± 0.04 0.25 ± 0.06 3.92 ±0.31 278 ± 19
C + D (46) 0.09 + 0.04 0.24 ± 0.06 3.17 + 0.25 241 ± 17
Diameter
^4  cm (44) 0.10 ±0.05 0.27 + 0.08 3.47 + 0.27 248 ± 18
>4 cm (56) 0.08 ± 0.03 0.23 ± 0.06 3.65 ± 0.30 271 ± 19
a No significant differences were noted,
Mean ± SE.
and dichotomized GST parameters is depicted in Table 5. Except for 
a significantly higher percentage of females with tumors containing 
high levels of GST-ju, (>0.18 /xg/mg protein), no significant differ­
ences were noted. However, a relatively high percentage of patients 
younger than 66.1 years had tumors with high GST-a (>0.14 ju-g/mg 
protein) or low GST-/J, (<0.18 /xg/mg protein) concentrations, but 
differences were not significant.
In the multivariate Cox model, containing all clinicopathological 
parameters, Dukes stage (HR, 2.70; P < 0,001) and age (HR, 2.82; 
P = 0.001) were the only significant prognostic parameters (Table 3). 
When the GST parameters were added separately to the multivariate 
Cox analysis model containing all clinicopathological parameters, 
GST-7T level (HR, 3.12; P — 0.002) and GST enzyme activity (HR, 
1.97; P = 0.020) were significant prognostically, whereas GST-a 
(HR, 1.59; P = 0.226) and GST-jul (HR, 1.75; P = 0.093) lost their 
prognostic significance from the univariate analyses (see Fig. 2, E and 
F, and Table 4).
DISCUSSION
GST activity in normal colonic mucosa is mediated largely by 
GST-tt; only minor levels of GST-a and GST-/x are found. When 
compared to the adjacent normal mucosa, GST-a and GST-/X are 
usually lower, whereas the levels of GST-tt and GST enzyme activ­
ities are higher in colorectal tumors (6-9). In the current analysis, 
GST-a and GST-p, were detected in only 22 and 40% of the tumors,
Table 2 Glutathione S-transferase subclass composition and GST enzyme activity of
colorectal adenocarcinomas in relation to overall survivala
Alive (n = 43) Dead (n = 57)
GST-a (jüLg/mg protein) 0.04 + 0.03^ 0.12 + 0.04
GST-/1 (jLLg/mg protein) 0.33 + 0.08 0.18 ± 0.05
GST-tt (/xg/mg protein) 3.22 + 0.26 3.84 + 0.30
GST activity (nmol/min/mg protein) 252 1 21 267 ± 17
a No significant differences were noted. 
h Mean ± SE.
respectively, and concentrations were generally low. GST-tt was the 
major GST subclass detected in almost all samples, and as a result, 
there was a significant linear correlation between GST-tt level and 
GST enzyme activity in the tumors. The level of GST-/X and GST-a 
was not correlated significantly with the GST-tt level, GST enzyme 
activity, or with each other.
Within the GST-jm family, one member, designated GSTM1-1, 
exhibits a genetic polymorphism. Due to this polymorphism, 40-50% 
of the western population has no functional GSTM1 allele (18-21). In 
smokers, absence of GSTM1-1 has been associated with an increased 
risk of developing squamous cell carcinoma of the lung (22, 23), as 
well as with the development of urinary bladder (19, 24) or larynx 
cancer (24). Strange et al. (18) reported an increased risk of devel­
oping gastric or colorectal cancer in GSTM1-1-deficient individuals, 
illustrated by a group of 26 colorectal cancer patients, of whom 62% 
was GSTM1—1 deficient. Zhong et al. (21) reported that 56% of their 
196 colorectal cancer patients was GSTM1-1 deficient, which was 
significantly more than the 42% detected in 225 controls. They also 
reported that the difference was much more pronounced in patients 
with tumors in the proximal colon (71% GSTM1-1 negative) than in 
the sigmoid colon or rectum (54% GSTM1-1 negative). In contrast, in 
the present study, 19 of the 35 carcinomas (54%) located in the right 
side of the colorectum, and 41 of the 65 carcinomas (63%) located in 
the left side of the colorectum were GSTM1-1 negative. Overall, 60 
of the 100 patients with colorectal cancer were GSTM1-1 negative. In 
earlier studies we found that in different groups of colorectal cancer 
patients, 17 of the 50 (25) and 12 of the 24 (6) individuals lacked the 
GSTM1-1 isotype. From all 174 colorectal cancer patients analyzed 
by our group thus far, 89 (51%) were found to be GSTM1-1 negative. 
This figure is not different from the 40-50% reported for the general 
population (18-21). Thus, our data do not support the hypothesis that 
individuals with a GSTM1—1 deficiency have an increased risk of 
developing colorectal cancer.
Many studies have been performed to investigate clinical, pathological, 
genetic, and biochemical variables of colorectal adenocarcinomas with
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Table 3 Univariate and multivariate analyses of dichotomized clinicopathological parameters in relation to overall survival
a C [, confidence interval. 
^NS, not significant.
Parameter dichotomized
(n)
No. of survivors 
(%)
Gender
Male (58) 25 (43)
Female (42) 18 (43)
Age
<66.1 years (43) 29 (67)
>66.1 years (57) 14(25)
Localization
Left (65) 30 (46)
Right(35) 13(37)
Differentiation grade
Poor (54) 24 (44)
Moderate/well (46) 19(41)
Histological type
Nonmucinous (75) 34 (45)
Mucinous (25) 9(36)
Dukes stage
A + B (54) 32 (59)
C + D (46) 11 (24)
Diameter
^4  cm (44) 19 (43)
>4 cm (56) 24 (43)
Cox proportional hazard analysis (95% CIÖ; P)
Univariate hazard 
ratio
1.07 (0.63-1.80; NS*)
3.14 (1.71-5.76;<0.001)
1.22 (0.72-2.08; NS)
1.18 (0.70-1.99; NS)
1.50 (0.84-2.67; NS)
2.71 (1.58-4.65;<0.001)
1.00(0.59-1.69; NS)
Multivariate hazard 
ratio
1.27(0.73-2.23; NS)
2.82 (1.52-5.25;0.001)
1.29 (0.72-2.30; NS)
1.36(0.80-2.32; NS)
1.27(0.69-2.31; NS)
2.70 (1.53~4.75;<0.001)
1.13(0.75-2.31; NS)
respect to their prognostic value in patients with this type of cancer 
(26-33). The most powerful clinicopathological prognostic factor in 
patients with colorectal carcinoma is still the extent of tumor spread (29, 
34-37), often classified by the staging system proposed originally by 
Dukes (11-13). The association between survival and the Dukes stage of 
the tumor was confirmed in the present study; of all clinicopathological 
parameters incorporated in the overall survival model (patient gender and 
age, tumor stage, histological type, differentiation grade, localization, and 
diameter), only the Dukes stage of the tumor and the age of the patient 
were statistically significantly related to overall survival in both the 
univariate and the multivariate Cox proportional hazard analysis. We 
recently studied the prognostic relevance of plasminogen activators and 
their inhibitors in a similar, partially overlapping group of colorectal 
cancer patients (32). Results with respect to the prognostic value of 
clinicopathological parameters for overall survival were comparable to 
the findings of the present study; only Dukes stage and age were statis­
tically significant. The finding that age was an important prognostic 
factor is in agreement several other studies (29, 34, 35), although the
effect of age may have been augmented by the fact that we analyzed 
overall survival and not only cancer-related deaths.
Some studies have indicated that poor differentiation of colorectal 
carcinomas is associated with shorter survival (34, 36); however, this 
could not be confirmed in our relatively small group of patients. The 
histological type of the tumors also had no statistically significant 
prognostic value, but patients with a mucinous carcinoma seemed to 
have a slightly worse prognosis, which is in agreement with the results 
of Green et al (38). With respect to the localization of the tumor, i.e., 
left versus right sided, no differences in survival were noted, which is 
in agreement with results reported by others (36, 37).
No significant association of GST parameters with patient (age and 
gender) or tumor (stage, histological type, differentiation grade, lo­
calization, and diameter) characteristics were detected in the 100 
tumors analyzed, Previous studies of breast tumors (10, 39), gastric 
carcinomas (40), and ovarian cancer (41) also failed to notice signif­
icant associations between clinicopathological factors and GST 
parameters.
Table 4 Univariate arid multivariate analyses of dichotomized glutathione S-transferase parameters in tumors in relation to overall sumval
Parameter dichotomized (h) No. of survivors (%)
a Cl, confidence interval.
b
Cox proportional hazard analysis (95% Cla; P)
Univariate hazard ratio Adjusted hazard ratio'
GST-a O-ig/mg protein)
<0.14 (86) 41 (48) »
>0.14 (14) 2(14) 2,40 (1.25-4.58;0.008)
1.59(0.75-3.36; NSC)
GST-ju. (ju,g/mg protein)
>0.18 (29) 17 (59)
<0.18 (71) 26 (37) 1,95 (1.03-3.69;0.040) 1.75(0.91-3.37; NS)
GST-7T (p-g/mg protein)
£5.30 (86) 40 (47)
>5.30 (14) 3(21) 1.92 (0.99-3.71 ;0.054) 3.12 (1.54-6,33;0.002)
GST activity (nmol/min/mg protein) Ï
<243 (53) 28 (53)
>243 (47) 15 (32) 1.66 (0.98-2.81;0,058) 1.97 (1.11-3,51;0.020)
Adjustment was performed by adding the glutathione S-transferase parameters separately to a model containing all clinicopathological parameters (gender, age, localization, 
diameter, differentiation grade, histological type, and Dukes stage). 
c NS, not significant.
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Tabic 5 Association between dichotomized glutathione S-transferase levels and
dichotomized clinicopathological parameters
No. of No. of No. of No. of
tumors tumors tumors tumors with
with GST-a with GST-/x with GST--JT GST activity <243
Parameter <0.14 /xg/mg >0.18 ju,g/mg <5.30 p.g/mg nmol/min/mg
dichotomized (n) protein (%) protein (%) protein (%) protein (%)
Gender
Male (58) 49 (84) 12(21) 51 (88) 33 (57)
Female (42) 37 (88) 17 (40)" 35 (83) 20 (48)
Age
<66.1 years (43) 40 (93) 15 (35) 37 (86) 24 (56)
>66.1 years (57) 46 (81) 14 (25) 49 (86) 29(51)
Localization
Left (65) 57 (88) 17(26) 55 (85) 37(57)
Right (35) 29 (83) 12(34) 31 (89) 16 (46)
Differentiation grade
Poor (54) 49 (91) 15 (28) 45 (83) 33 (61)
Moderate/well (46) 37 (80) 14 (30) 41 (89) 20 (43)
Histological type
Nonmucinous (75) 66 (88) 21 (28) 65 (87) 37 (49)
Mucinous (25) 20 (80) 8(32) 21 (84) 16 (64)
Dukes stage
A + B (54) 48 (89) 16 (30) 46 (85) 27 (50)
C + D (46) 38 (83) 13 (28) 40 (87) 26 (57)
Diameter
£4  cm (44) 38 (86) 13 (30) 38 (86) 24 (55)
>4 cm (56) 48 (86) 16 (29) 48 (86) 29 (52)
a Statistically significant versus male glutathione 5-transferase (x (P < 0.005).
Previous studies have shown that most gastrointestinal tumors 
contain increased amounts of GST-ît and GST enzyme activity when 
compared to adjacent normal mucosa (4, 6-9,42, 43), suggesting that 
these elevated levels may offer a selective advantage to the tumor 
cells. In the present study we analyzed the prognostic relevance of the 
GST system to the overall survival of patients with colorectal adeno­
carcinomas. Comparing mean GST parameters of survivors with those 
of nonsurvivors, only minor differences were found. However, opti­
mal dichotomization using the univariate Cox proportional hazard 
model revealed that patients with tumors containing a high level of 
GST-a or a low level of GST-[jl had a significantly shorter survival. 
A high concentration of GST-tt or a high GST enzyme activity also 
were associated with a shorter survival period, but the differences 
reached only borderline significance in the univariate analyses. In 
contrast, GST-u level and GST enzyme activity were significant 
prognostic parameters when added separately to a multivariate Cox 
model, which contained all clinicopathological parameters analyzed. 
Since GST-tt was the major subclass detected in almost all samples 
analyzed, GST enzyme activity was correlated significantly with 
GST-tt levels in the tumors. When GST-a and GST-ju, levels were 
added to this multivariate Cox model, both had no significant inde­
pendent prognostic value, probably because these two GST subclasses 
had a slight, nonsignificant association with age. These results indi­
cate that in this group of patients, GST-7T concentration and GST 
enzyme activity in the carcinoma are prognostic variables for the 
overall survival that are independent from the clinicopathological 
parameters, whereas GST-a and GST-ju, are dependent prognostic
variables.
GSTs are involved in the metabolism of several types of anticancer 
drugs (3). In addition, increased GST concentrations have been im­
plicated as a resistance mechanism in cell lines selected for resistance 
toward various cytostatic drugs (4). Therefore, most studies concern­
ing the possible prognostic value of tumoral GST levels on patient 
survival aimed at malignancies from patients who were treated 
subsequently with anticancer drugs. Studies by Wright et al (44) and 
Peters et al (39) in advanced breast cancer, Murphy et al (45) 
and van der Zee et ai (46) in ovarium tumors, Joncourt et al (47) in
leukaemia, and Okuyarna et al (40) in gastric cancer did not show a 
significant correlation between pretreatment GST levels and response 
to chemotherapy or survival. In contrast, studies in ovarium tumors by 
Green el al (48) and Hamada et al (41) indicated that a low level of 
GST-tt in the malignant tissue was prognostic for response to chem­
otherapy and prolonged survival, and Tidefeld et al (49) reported a 
significant correlation between low GST-tt expression at time of 
diagnosis and response to treatment in acute nonlymphoblastic 
leukaemia.
Moreover, Gilbert et al (10) reported that a high GST-tt level in the 
tumor was a significant predictor of early recurrence and death in 
node-negative breast cancer patients who received primary curative 
surgery without adjuvant chemotherapy. Recently, Grignon et al (50) 
reported a possible prognostic value for GST-7T levels in patients with 
renal cell carcinoma treated by radical nephrectomy only. Our study 
also indicates that GST-tt level and GST enzyme activity in colorectal 
tumors may be of prognostic relevance for overall survival. These 
GST values may provide clinically useful prognostic parameters 
through which patients could be selected for adjuvant treatment.
It is not apparent from the present analysis why increased GST-tt 
levels and GST enzyme activities in carcinomas are linked to a poorer 
prognosis in patients with colorectal cancer. The elevated levels of 
GST-tt in most gastrointestinal carcinomas suggests that malignant 
cells are under a selective stress that favors cells with high GST-tt 
content. However, it is also feasible that the GST isoenzymes them­
selves do not offer the selective advantage, but one or more of the 
GST genes are linked genetically or transcriptional to genes coding 
for other proteins that are involved in the clinical course of the 
disease, as suggested by Gilbert et al (10). Further analysis of genes 
and proteins, the expression of which is linked to those of GSTs, may 
provide new ways to discriminate colorectal cancer patients with 
respect to their survival prognosis.
In conclusion, GST-tt levels and GST enzyme activities in tumors 
of patients with colorectal adenocarcinoma are prognostic variables 
for overall survival independent from clinicopathological parameters 
and might form a basis for selective adjuvant therapy.
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